Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
First Claim
1. A pharmaceutical composition, comprising:
- a) a non-cationic liposome; and
b) a physiologically acceptable carrier.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.
-
Citations
22 Claims
-
1. A pharmaceutical composition, comprising:
-
a) a non-cationic liposome; and
b) a physiologically acceptable carrier. - View Dependent Claims (2, 6, 7, 8, 9, 10, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
3. A pharmaceutical composition, comprising:
-
a) a liposome, and b) a physiologically acceptable carrier, wherein the liposome is comprised of ceramide and at least one lipid. - View Dependent Claims (11, 12, 13)
-
-
4. A pharmaceutical composition, comprising:
-
a) a liposome, and b) a physiologically acceptable carrier, wherein the liposome is comprised of sphingosine and at least one lipid.
-
-
5. A pharmaceutical composition, comprising:
-
a) a liposome, and b) a physiologically acceptable carrier, wherein the liposome is comprised of sphingosine 1-phosphate and at least one lipid. - View Dependent Claims (14)
-
Specification